Very clever.
The SurgCentre sites become the clinical trial sites for the next CLBP trial. The sites generate extra volume from the trial participants and with a little bit of cream of the top for trial costs it may even be a net earner.
MSB move away from the treatment as a restorative or replacement disc therapy which requires improvement on both pain and function. So earlier stage of problems where pain reduction on its own can become the primary endpoint; naturally at much lower pricing to be cost-effective.
CHF is put out as a partnering opportunity. MSB can battle it with the FDA over agvd.
It is very creative – and SI is certainly not just a pretty face.
Ann: Mesoblast Raises US$110M Led By US Strategic Investor Group, page-85
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |